Skip to main content
. 2019 Mar 14;11:2129–2138. doi: 10.2147/CMAR.S184922

Figure 1.

Figure 1

Kaplan–Meier curves for iPFS in advanced EGFR-mutant NSCLC patients.

Notes: The median iPFS is significantly longer in patients receiving concurrent EGFR-TKIs and WBRT than in those given EGFR-TKIs alone (17.7 vs 11.0 months, P=0.015).

Abbreviations: iPFS, intracranial progression-free survival; NSCLC, non-small-cell lung cancer; TKI, tyrosine kinase inhibitor; WBRT, whole-brain radiotherapy.